This pilot trial aimed to study the feasibility and effects on quality of life (QOL) and well-being of short-term fasting (STF) during chemotherapy in patients with gynecological cancer.
Authors: Stephan P. Bauersfeld, Christian S. Kessler, Manfred Wischnewsky, Annette Jaensch, Nico Steckhan, Rainer Stange, Barbara Kunz, Barbara Brückner, Jalid Sehouli and Andreas Michalsen
Melanoma brain metastasis is associated with an extremely poor prognosis, with a median overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV melanoma has been significantl...
Authors: Elham Vosoughi, Jee Min Lee, James R. Miller, Mehdi Nosrati, David R. Minor, Roy Abendroth, John W. Lee, Brian T. Andrews, Lewis Z. Leng, Max Wu, Stanley P. Leong, Mohammed Kashani-Sabet and Kevin B. Kim
Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensit...
Authors: Clizia Zichi, Marco Tampellini, Marcello Tucci, Cristina Sonetto, Chiara Baratelli, Maria P. Brizzi and Giorgio V. Scagliotti
Radiogenic angiosarcoma of the breast (RASB) is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized t...
Authors: Askin Dogan, Peter Kern, Beate Schultheis, Günther Häusler, Günther A. Rezniczek and Clemens B. Tempfer
5-Fluorouracil (5FU), Folinic acid (FA), and Oxaliplatin (FOLFOX) or 5FU, FA, and Irinotecan (FOLFIRI) are standard regimens for palliative chemotherapy of metastatic colon cancer. Since data showing the influ...
Authors: Stefan Munker, Michael Gerken, Petra Fest, Claudia Ott, Elisabeth Schnoy, Stefan Fichtner-Feigl, Philipp Wiggermann, Martin Vogelhuber, Wolfgang Herr, Christian Stroszczynski, Hans Jürgen Schlitt, Matthias Evert, Michael Reng, Monika Klinkhammer-Schalke and Andreas Teufel
The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of mole...
Authors: Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite and Elona Juozaityte
Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line trea...
Authors: Seiji Ito, Yasuo Ohashi and Mitsuru Sasako
To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with small hepatocellular carcinoma(sHCC) who were ineligible for surgery or ablation therapies.
Authors: Tao Zhang, Jing Sun, Weiping He, Huan Li, Junjie Piao, Huijun Xu and Xuezhang Duan
To identify the incidence, recurrence pattern and prognosis of brain metastases (BM) among women with metastatic triple negative breast cancer (mTNBC) treated consecutively at a single institution during a 7-y...
Authors: Jia Jin, Yu Gao, Jian Zhang, Leiping Wang, Biyun Wang, Jun Cao, Zhimin Shao and Zhonghua Wang
Volumetric-modulated arc therapy (VMAT) is a highly sophisticated linear accelerator-based treatment method, and allows dose rate-changing intensity modulation with gantry rotation. We report our clinical expe...
Authors: Yuri Jeong, Jinhong Jung, Byungchul Cho, Jungwon Kwak, Chiyoung Jeong, Jong Hoon Kim, Jin-hong Park, So Yeon Kim, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee and Sang Min Yoon
SMARCB1 (INI1) is a tumor-suppressor gene located at 22q11.2. Loss of SMARCB1 protein expression has been reported to be associated with atypical teratoid/rhabdoid tumors and malignant rhabdoid tumors of the kidn...
Authors: Kazushi Yoshida, Yutaka Fujiwara, Yasushi Goto, Takashi Kohno, Akihiko Yoshida, Koji Tsuta and Yuichiro Ohe
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. M...
Authors: Lu Xie, Wei Guo, Ye Wang, Taiqiang Yan, Tao Ji and Jie Xu
Treatment of recurrent nasopharyngeal carcinoma is a challenging clinical problem. We report the case of a 46 year old male showing excellent response and signs of immunostimulation following re-re-irradiation...
Authors: T. Finazzi, T. Rordorf, K. Ikenberg, G. F. Huber, M. Guckenberger and H. I. Garcia Schueler
Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource imp...
Authors: Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang and Ming Kuang
Recent studies have reported a relationship between prognosis and neutrophil-to-lymphocyte ratio (NLR) in patients with head and neck cancer (HNC). As the results are still controversial, we conducted a meta-a...
Authors: Yalian Yu, Hongbo Wang, Aihui Yan, Hailong Wang, Xinyao Li, Jiangtao Liu and Wei Li
Knowledge about disease and treatment is necessary before patients can consent to treatment. One of the few established instruments for evaluating whether sufficient information has been provided, is the EORTC...
Authors: Ola Berger, Bjørn Henning Grønberg, Jon Håvard Loge, Stein Kaasa and Kari Sand
A randomized trial demonstrated that capecitabine is at least as effective as fluorouracil in the adjuvant treatment of patients with locally advanced rectal cancer. However, not all patients receive all plann...
Authors: Flavius Sandra-Petrescu, Florian Herrle, Iris Burkholder, Peter Kienle and Ralf-Dieter Hofheinz
Treatment of localized gastric cancer (LGC) consists of surgical resection followed by adjuvant treatment. Both chemoradiation (CRT) and chemotherapy (CT) regimens have shown benefit in survival outcomes versu...
Authors: Daniel M. Girardi, Mariana A. de Lima, Gabriel C. B. Pereira, Marcelo V. Negrão, Rossana V. M. López, Fernanda C. Capareli, Jorge Sabbaga and Paulo Marcelo G. Hoff
Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduc...
Authors: Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang, Jerald P. Radich, Vivian G. Oehler, Javier Pinilla-Ibarz, Michael W. N. Deininger, Li Lin, Richard A. Larson, Michael J. Mauro, Joseph O. Moore, Ellen K. Ritchie, Neil P. Shah, Richard T. Silver, Martha Wadleigh…
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-li...
Authors: Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, Wan-Teck Lim, David Bin-Chia Wu and Kwong Ng
In this prospective non-interventional study, the effectiveness and tolerability of erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after ≥1 platinum-based chemotherapy were assessed.
Authors: Wolfgang M. Brueckl, H. Jost Achenbach, Joachim H. Ficker and Wolfgang Schuette
HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about it...
Authors: Yan Wang, Shijia Zhang, Fengying Wu, Jing Zhao, Xuefei Li, Chao Zhao, Shengxiang Ren and Caicun Zhou
Fasting in disease prevention and treatment has recently become a popular topic, particularly in the context of oncology. Unfortunately, the growing attention paid by the media has created a background of spec...
Authors: Riccardo Caccialanza, Emanuele Cereda, Francesco De Lorenzo, Gabriella Farina and Paolo Pedrazzoli
Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for locally advanced nasopharyngeal carcinoma (LA-NPC). Neoadjuvant chemotherapy foll...
Authors: Jiraporn Setakornnukul and Kullathorn Thephamongkhol
Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients w...
Authors: Hao Peng, Ling-Long Tang, Xu Liu, Lei Chen, Wen-Fei Li, Yan-Ping Mao, Yuan Zhang, Li-Zhi Liu, Li Tian, Ying Guo, Ying Sun and Jun Ma
We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGF...
Authors: Isa Mambetsariev, Lalit Vora, Kim Wai Yu and Ravi Salgia
Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model f...
Authors: Hwi Young Kim, Dong Hyeon Lee, Jeong-Hoon Lee, Young Youn Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim and Jung-Hwan Yoon
The expression of circular RNA (circRNA) may affect tumor progression. However, there have been no systemic meta-analysis for cancer diagnosis by using circRNAs in clinical till now. Herein, we aimed to collec...
Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety o...
Authors: Taiki Hakozaki, Yusuke Okuma and Jumpei Kashima
Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established.
Authors: M. P. Brizzi, A. La Salvia, M. Tampellini, C. Sonetto, M. Volante and G. V. Scagliotti
In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dos...
Authors: Anikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, Éva Szilágyi, Zoltán Varga, János Révész, Renáta Kószó, Linda Varga and Zsuzsanna Kahán
Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data availabl...
Authors: Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing and Yung-Jue Bang
To compare the prevalence of nephrotoxicity between patients with a solitary-functioning kidney versus those with bilateral-functioning kidneys during the administration of cisplatin-based chemotherapy for adv...
Mainly because of the diversity of clinical presentations, diagnostic delays in lymphoma can be excessive. The time spent in primary care before referral to the specialist may be relatively short compared with...
Authors: Xavier Bosch, Carmen Sanclemente-Ansó, Ona Escoda, Esther Monclús, Jonathan Franco-Vanegas, Pedro Moreno, Mar Guerra-García, Neus Guasch and Alfons López-Soto
The primary pulmonary lymphoma (PPL), with a low incidence, was highly misdiagnosed in clinic. The present study analyzes the clinical features, laboratory and imaging data, pathologic characteristics, and sum...
Authors: D. Yao, L. Zhang, P. L. Wu, X. L. Gu, Y. F. Chen, L. X. Wang and X. Y. Huang
Here we assessed the influence of androgen deprivation therapy (ADT) during and/or after post-prostatectomy radiotherapy (RT) on biochemical recurrence (BCR) and radiographic progression in patients with prost...
Authors: Myong Kim, Cheryn Song, In Gab Jeong, Seung-Kwon Choi, Myungchan Park, Myungsun Shim, Young Seok Kim, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim and Hanjong Ahn
Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (...
Authors: Megan E. V. Caram, Jason P. Estes, Jennifer J. Griggs, Paul Lin and Bhramar Mukherjee
Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicente...
Authors: Dae-Won Lee, Kyung-Hun Lee, Hee-Jun Kim, Tae-Yong Kim, Jin-Soo Kim, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Seock-Ah Im and Tae-You Kim
Esophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesis remain largely unknown.
Authors: Hongyang Lu, Shifeng Yang, Huineng Zhu, Xiaoling Tong, Fajun Xie, Jing Qin, Na Han, Xue Wu, Yun Fan, Yang W. Shao and Weimin Mao
There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemother...
Authors: Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang and Zhen-ning Wang
Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can ...
Authors: Surabhi Ranjan, Martha Quezado, Nancy Garren, Lisa Boris, Christine Siegel, Osorio Lopes Abath Neto, Brett J. Theeler, Deric M. Park, Edjah Nduom, Kareem A. Zaghloul, Mark R. Gilbert and Jing Wu
The immune system has a known role in the aetiology, progression and final treatment outcome of oral squamous cell cancers. The aim of this study was to evaluate the influence of radical surgery and radiothera...
Authors: Tadej Dovšak, Alojz Ihan, Vojko Didanovič, Andrej Kansky, Miha Verdenik and Nataša Ihan Hren
Cancer stem cells (CSCs) are believed to promote the malignant transformation of breast cancer via multiple signaling pathways, including the Wnt/β-catenin pathway. Leucine-rich repeat-containing G protein-cou...
Authors: Ming-Feng Hou, Po-Ming Chen and Pei-Yi Chu
Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.
Authors: Yu Qiao, Jihong Yang, Lili Liu, Yixin Zeng, Jie Ma, Jing Jia, Li Zhang, Xiaoguang Li, Peihong Wu, Wenchao Wang, Dongge Liu, Huan Chen, Yunbo Zhao, Huan Xi and Yao Wang
Gamma Knife radiosurgery (GKRS) is increasingly applied in patients with multiple brain metastases and is expected to have less adverse effects in cognitive functioning than whole brain radiation therapy (WBRT...
Authors: Wietske C. M. Schimmel, Eline Verhaak, Patrick E. J. Hanssens, Karin Gehring and Margriet M. Sitskoorn
Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs...
Authors: Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne and Isabelle Durand-Zaleski
Survival advantage following trans-arterial chemoembolization (TACE) is variable in patients with hepatocellular carcinoma (HCC). We combined pre-TACE radiologic features to derive a novel prognostic signature...
Authors: David J. Pinato, Madhava Pai, Isabella Reccia, Markand Patel, Alexandros Giakoustidis, Georgios Karamanakos, Azelea Rushd, Shiraz Jamshaid, Alberto Oldani, Glenda Grossi, Mario Pirisi, Paul Tait and Rohini Sharma
To evaluate the prevalence of metastatic tumors involving the myocardium and study their presentation in order to increase awareness to their existence.
Authors: Ivana Burazor, Sarit Aviel-Ronen, Massimo Imazio, Orly Goitein, Marina Perelman, Natalia Shelestovich, Ninoslav Radovanovic, Vladimir Kanjuh, Iris Barshack and Yehuda Adler
